Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
Authors' conclusion
Dapagliflozin increased hemoglobin and reduced ferritin and urinary markers of inflammation, suggesting potentially important effects on iron metabolism and inflammation.
Study context
- Population
- Patients with T2D and albuminuria360 with biosamples
- Participants
- 461 patients
- Comparison
- Dapagliflozin or dapagliflozin-saxagliptin vs placebo
Primary result
As reported in the abstract
week 24
Each group vs placeboHemoglobin increase, g/L (95% CI)P value
Dapagliflozin
5.7(4.0–7.3)
P < 0.001Dapagliflozin-saxagliptin
4.4(2.7–6.0)
P < 0.001- Dapagliflozin · lower with Dapagliflozin
- ferritin reduction 18.6 % (95% CI 8.7–27.5); P < 0.001
- Dapagliflozin-saxagliptin · lower with Dapagliflozin-saxagliptin
- ferritin reduction 18.4 % (95% CI 8.7–27.1); P < 0.001
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| Urinary inflammatory markers · week 24Dapagliflozin vs Placebo · lower with Dapagliflozin | urinary MCP-1/Cr reduction 29.0 % (CI 14.6–41.0) | P < 0.001 |
| Urinary inflammatory markers · week 24Dapagliflozin vs Placebo · lower with Dapagliflozin | urinary IL-6/Cr reduction 26.6 % (CI 9.1–40.7) | P = 0.005 |
Urinary inflammatory markers · week 24
- No changes in other markers with dapagliflozin
Original publication
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial. Cardiovasc Diabetol. Published 28 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →